OR WAIT 15 SECS
Novation, a healthcare contracting services company based in Texas, has contracted with McKesson Corp?s OneStop Generics Program for its mutual health system customers.
Novation, a healthcare contracting services company based in Texas, has contracted with McKesson Corp’s OneStop Generics Program for its mutual health system customers.
McKesson said its OneStop program helps pharmacies to “take full advantage of the significant pricing advantage of generic drugs through a dedicated team of generics specialists and direct access to the latest product information and industry news.”
McKesson said Novation’s customers will benefit from its generics product availability and sourcing consistency from a predictable supply chain and that will enhance medication safety for hospitals.
Novation’s pharmacy distributors, including AmerisourceBergen, Cardinal Health, McKesson and Morris & Dickson, will offer their non-injectable generic programs to members of VHA Inc, University HealthSystem Consortium (UHC), and Provista. The drug program includes tablets, capsules, topical creams and ointments, ophthalmic and optic solutions, oral liquids and respiratory products.
“While further demonstrating McKesson’s generics leadership, the extension of McKesson’s OneStop Generics Program to Novation members underscores our single-minded focus on providing our pharmacy customers with the highest-quality service that helps them compete more effectively, particularly in today’s challenging economic environment,” John Figueroa, president, McKesson U.S. Pharmaceutical, said.
The OneStop Generics Program helps links customers with generic specialists. “Members spend more than $12.5 billion a year through Novation’s comprehensive pharmacy portfolio which features nearly 10,000 products,” said Mick Hunt, vice president, pharmacy at Novation. “Non-injectable generics are commodity products that represent about 3 percent of member pharmacy spend.”
Hunt adds, “Most members of VHA, UHC and Provista already purchase a portion of their non-injectable generic drugs through their distributor’s contracts so we expect the transition to be seamless. We look forward to working with our pharmacy distributors to offer our mutual customers enhanced value and service.”